ROS1 and neoplasm: These mutations include TP53 c.818G>T (p.R273L), ROS1 c.2370_2395delinsC (p.S791Pfs11), and BRCA2 c.3599_3600del (p.C1200*), each of which significantly impacts protein function and contributes to tumor behavior and therapeutic resistance (Figures 3B, C).